Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing
Darius Noack, Johannes Wach, Alonso Barrantes-Freer, Nils H Nicolay, Erdem Güresir, Clemens Seidel · 2024
Read Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing by Darius Noack, Johannes Wach, Alonso Barrantes-Freer, Nils H Nicolay, Erdem Güresir, Clemens Seidel (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590270.txt.
Description
Darius Noack and co-authors pool patient data to price the survival cost of a gene loss in brain tumors. Their 2024 study deals with loss of both copies of the CDKN2A/B genes in gliomas, low and high grade. Past series were mixed, so a clean risk read was missing. The team rebuilt single-patient data from past papers for survival by gene state. They also scored a cheaper stain test that hints at the loss.
The loss was far more common in tumors lacking a key mutation than in those with it. In both tumor kinds, the loss cut median survival, in one kind by a third and in the other by more than half. The stain test missed some losses, the pooled data show.
Catalog record
| CREATOR | Darius Noack, Johannes Wach, Alonso Barrantes-Freer, Nils H Nicolay, Erdem Güresir, Clemens Seidel |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |